Trial Profile
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization: SIRTAX Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2016
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Sirolimus (Primary)
- Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms SIRTAX-LATE
- 06 Jun 2011 Results published in Circulation.
- 05 Nov 2010 New trial record.